Clinical Trial Results:
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHERAPY IN PATIENTS WHO ARE ctDNA POSITIVE AFTER SURGICAL RESECTION OF STAGE II-III NON-SMALL CELL LUNG CANCER.
Summary
|
|
EudraCT number |
2019-003449-14 |
Trial protocol |
GB DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Jun 2023
|
First version publication date |
09 Jun 2023
|
Other versions |
|
Summary report(s) |
Results statement GO41836 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.